{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:07Z","timestamp":1790710147695,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108334","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:01:24Z","timestamp":1756450884000},"page":"108334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of rituximab and low dosage of glucocorticoids for ANCA associated vasculitis interstitial lung disease: a proof-of-concept study"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-6606","authenticated-orcid":false,"given":"Edoardo","family":"Conticini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-2882","authenticated-orcid":false,"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-2469","authenticated-orcid":false,"given":"Silvia","family":"Grazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-5722","authenticated-orcid":false,"given":"Miriana","family":"d\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bergantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1036-5322","authenticated-orcid":false,"given":"Tommaso","family":"Pianigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Mancianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.108334_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/keac339","article-title":"Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality","volume":"62","author":"Doliner","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmed.2025.108334_bib2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.autrev.2017.05.008","article-title":"Interstital lung disease in ANCA vasculitis","volume":"16","author":"Alba","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.rmed.2025.108334_bib3","first-page":"221","article-title":"Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis","volume":"38","author":"Sebastiani","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.rmed.2025.108334_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/biology11010094","article-title":"KL-6 in ANCA-associated vasculitis patients with and without ILD: a machine learning approach","volume":"11","author":"Conticini","year":"2022","journal-title":"Biology"},{"issue":"13","key":"10.1016\/j.rmed.2025.108334_bib5","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.3390\/jcm11133835","article-title":"Anti-inflammatory and\/or anti-fibrotic treatment of MPO-ANCA-Positive interstitial lung disease: a short review","volume":"11","author":"Yamakawa","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.rmed.2025.108334_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/0961203316640921","article-title":"Diagnostic ANCA algorithms in daily clinical practice: evidence, experience, and effectiveness","volume":"25","author":"Avery","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.rmed.2025.108334_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.rmed.2025.108334_bib8","first-page":"821","article-title":"Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian society for Rheumatology","volume":"41","author":"Manfredi","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.rmed.2025.108334_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14740338.2021.1973428","article-title":"Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases","volume":"21","author":"Vicente-Rabaneda","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rmed.2025.108334_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102338","article-title":"Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor","volume":"106","author":"Maillet","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.rmed.2025.108334_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0038-1669914","article-title":"Antineutrophil cytoplasmic antibody-associated lung fibrosis","volume":"39","author":"Borie","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108334_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.581828","article-title":"Long-term Follow-Up of patients with idiopathic pulmonary fibrosis treated with pirfenidone or nintedanib: a real-life comparison study","volume":"7","author":"Cameli","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.rmed.2025.108334_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12890-021-01516-4","article-title":"Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study","volume":"21","author":"Song","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108334_bib14","article-title":"Presentation and progression of MPO-ANCA interstitial lung disease","volume":"8","author":"Salvati","year":"2024","journal-title":"J Transl Autoimmun"},{"issue":"1","key":"10.1016\/j.rmed.2025.108334_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12890-019-0969-5","article-title":"Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study","volume":"19","author":"Watanabe","year":"2019","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108334_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/jcm14010229","article-title":"Clinical profiles, survival, and lung function outcomes in ANCA-associated interstitial lung disease: an observational study","volume":"14","author":"Valero-Mart\u00ednez","year":"2025","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108334_bib17","article-title":"Systemic corticosteroids in fibrotic lung disease: a systematic review and meta-analysis","volume":"10","author":"Pitre","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.rmed.2025.108334_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12890-019-0880-0","article-title":"Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience","volume":"19","author":"Kawamura","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2025.108334_bib19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00296-021-04891-7","article-title":"Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients","volume":"41","author":"Yamaguchi","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.rmed.2025.108334_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00296-020-04752-9","article-title":"Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis","volume":"41","author":"Speer","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.rmed.2025.108334_bib21","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2025.108334_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/ard-2023-224343","article-title":"Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study","volume":"83","author":"Furuta","year":"2024","journal-title":"Ann. Rheum. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500397X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500397X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:05:46Z","timestamp":1761116746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112500397X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S095461112500397X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108334","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rituximab and low dosage of glucocorticoids for ANCA associated vasculitis interstitial lung disease: a proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108334"}}